Life Sciences

Mercy BioAnalytics, Inc. promoted its chief operating officer, Dawn Mattoon, to the CEO position. Former CEO and Co-founder Paul Blavin transitioned to vice chairman of the board.

Acton-based Insulet, a medical device firm specializing in diabetes treatment, has acquired $25 million in assets from Automated Glucose Control LLC in California.

Acton medical device firm Insulet has acquired $25 million of diabetes pump technology from California-based Bigfoot Biomedical, nearly doubling Insulet’s intellectual property.

Marlborough biopharma Phio Pharmaceuticals is ushering in a new strategic plan seeking to reposition the company from pure discovery research to full development, utilizing clinical trials.

A Worcester Polytechnic Institute professor of computer science led a team of researchers on a study using artificial intelligence to better predict suicide risk in women.

When Kathleen Jordan took a job at her university’s advancement office, she could not have predicted it would be the beginning of a decades-long career in fundraising.

Marlborough medical technology company Hologic Inc., reported a decrease in profits of 62.5%, to $187 million, in the first quarter of 2023, which in the same period of the previous year was $499 million.

The annual profits at Boston Scientific, a Marlborough medical device manufacturer, dropped to $698 million in 2022, down from $1.04 billion in 2021.

Watertown-based EyePoint Pharmaceuticals will design and construct a new manufacturing facility in Northbridge focused on development and commercialization of therapeutics for severe eye disorders.

The Worcester Red Sox plan on temporarily taking over the space set aside for the delayed Left Field Building, which is part of a five-building planned development slated to help pay for the $160-million public baseball stadium.